changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Please find below a list of our press releases.
19 Aug 2019
Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE:BTG) pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals.
15 Aug 2019
BTG International Canada Inc. announced it has received a medical device license from Health Canada for the ICEfx™ Cryoablation System.
BTG International Canada Inc., filiale de la société BTG plc (BTG à la Bourse de Londres) spécialiste mondial en produits médicaux, a annoncé l’approbation par Santé Canada de son système de cryoablation ICEfxMC.
23 Jul 2019
BTG plc (LSE: BTG), a global healthcare company, today announced consensus recommendations for personalised treatment for hepatocellular carcinoma (HCC) with TheraSphere™ have been published by an international multidisciplinary working group¹. In addition, data from the Dosisphere phase II dosimetry trial supports MAA SPECT/CT based prospective personalised dosimetry².
25 Jun 2019
Argentina now the second South American country to offer TheraSphere™ treatment for
liver cancer patients
Brazil to be the first South American country to offer TheraSphere® treatment for
liver cancer patients
5 Feb 2019
BTG plc (LSE: BTG), a global healthcare company, today announced that the NHS Specialised Services Commissioning Committee has agreed that, effective 1 April 2019, NHS England will routinely commission Selective Internal Radiation Therapy (SIRT) for colorectal cancer patients with liver-limited metastatic disease who are refractory or intolerant to chemotherapy.
21 Jan 2019
BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of an Australian patient with DC Bead LUMI™, a next-generation development of the market leading DC Bead®.
21 Dec 2018
An estimated 500 patients per year in France could be eligible for treatment with TheraSphere®
20 Sep 2018
September 20, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, today announced the global launch of the ICEfx™ Cryoablation System. ICEfx™, an evolution of the existing Visual ICE™ system, offers predictable, reliable performance with seamless therapy delivery and exceptional ease of technical operation. This compact and powerful console is designed for interventional radiologists who want to offer their patients state-of-the-art, minimally invasive treatment options.
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com